Insulet: New Corrective Action Appears Manageable, But May Raise Concerns of a Pattern; Reit UW

Research evidence excerpt

Insulet: New Corrective Action Appears Manageable, But May Raise Concerns of a Pattern; Reit UW

Equity Research

U.S. Medical Supplies & Devices

27 May 2026

Insulet

New Corrective Action Appears

Manageable, But May Raise Company Update

PODD UNDERWEIGHTConcerns of a Pattern; Reit UW

U.S. Medical Supplies & POSITIVE

Mgmt announced a second corrective action related to Devices Price Target USD 198.00

cannula manufacturing at its Acton, MA facility, with a Price (26-May-26) USD 153.80

different root cause from the March action. While the issue Potential Upside/Downside +28.7% Source: Bloomberg, Barclays Research

appears contained, we would not be surprised to see this

raise broader questions regarding PODD's quality function. U.S. Medical Supplies & Devices

Matt Miksic

+1 212 526 9189

matt.miksic@barclays.com

BCI, US

THE 2026 EXTEL SURVEY IS NOW OPEN William McMahon

+1 212 526 3816

Support our industry-leading william.mcmahon@barclays.comBCI, US

analysts with 5-Star votes in Sneha Muthe

this year’s Extel All-America +1snehakhagendra.muthe@barclays.com212 526 8385

Research Survey BCI, US

Vote Now View Analysts

Mgmt Announces a Second Corrective Action at the Acton, MA Facility: The May 26

announcement represents a more complex second event, involving a cannula tear (similar to

the March action) causing leakage of insulin in Omnipod 5, DASH, and Eros Pods. Mgmt

estimates that the manufacturing issue affected ~7M pods, which represents ~8.5% of total

global manufacturing production in 2025. Mgmt believes that the clinical impact is contained

(24 serious adverse events YTD and no deaths). Mgmt described this issue as more difficult to

detect, but like the March action, it was only related to manufacturing lines at the Acton facility.